The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
APVO | -99.11% | -100% | -90.76% | -100% |
S&P | +15.06% | +95.03% | +14.29% | +210% |
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $0.00M | 0.0% |
Gross Profit | -$0.05M | 46.2% |
Market Cap | $9.83M | 4671.3% |
Market Cap / Employee | $0.23M | 0.0% |
Employees | 42 | 5.0% |
Net Income | -$6.20M | -5.5% |
EBITDA | -$6.18M | -4.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $9.41M | 16.7% |
Inventory | 0 | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $4.21M | -16.2% |
Short Term Debt | $0.00M | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | -157.31% | -42.1% |
Return On Invested Capital | -109.88% | 5.4% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | -$7.09M | -15.3% |
Operating Free Cash Flow | -$7.09M | -15.3% |
Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
---|---|---|---|---|---|
Price to Book | 0.69 | 1.32 | -1.15 | -0.15 | -546.75% |
Price to Tangible Book Value | 121.65 | 8.99 | 7.12 | -0.15 | -100.60% |
Enterprise Value to EBITDA | 0.20 | -0.35 | -0.62 | 0.48 | 44.26% |
Return on Equity | -251.0% | -284.3% | -1023.9% | -437.3% | 79.42% |
Total Debt | $4.83M | $4.63M | $4.42M | $4.21M | -16.24% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.